MetaCap

Elutia (ELUT) vs Kalaris Therapeutics (KLRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elutia (ELUT) has outperformed Kalaris Therapeutics (KLRS) over the past year, gaining 52.6% versus a loss of 81.7%. Over five years, ELUT leads with a -82.8% price change compared with -99.7% for KLRS. Elutia is the larger company by market cap ($40.0 million vs $30.5 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELUT+52.56%KLRS-81.74%
+116%+13%-91%
Nov 21, 20251 yearNov 20, 2026
ELUT-84.48%KLRS-99.72%
+48%-30%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELUT versus KLRS key metrics
MetricELUTKLRS
Share price$0.9001$1.28
Market cap$39.96M$30.47M
1-day change+11.12%-5.19%
YTD return+29.88%-84.83%
1-year return+52.56%-81.74%
5-year return-82.76%-99.70%
EPS (TTM)$-0.68$-1.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$12.29M—
Revenue growth (YoY)-15.03%—
Net income (latest FY)$53.38M$-43.44M
Gross margin53.66%—
Operating margin-218.91%—
Net margin434.23%—
52-week high$1.39$11.88
52-week low$0.50$1.25
Distance from 52-week high-35.01%-89.23%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+455.49%+1361.72%
Average volume185.17K77.37K
Shares outstanding44.40M23.80M
Employees2520
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELUT has outperformed KLRS by 134.3 percentage points over the past year.

About Elutia

ELUT stock →

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees

About Kalaris Therapeutics

KLRS stock →

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees

ELUT vs KLRS FAQ

Which is bigger, Elutia or Kalaris Therapeutics?

Elutia (ELUT) is larger, with a market capitalization of $39.96M compared with $30.47M for Kalaris Therapeutics (KLRS).

Which stock has performed better over the past year, ELUT or KLRS?

ELUT returned +52.56% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.

Are Elutia and Kalaris Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons